Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhubarb + mirabilite is a traditional Chinese medicine (TCM) combination therapy frequently employed for its potent anti-inflammatory, anti-edematous, and antimicrobial properties. The combination typically consists of the dried root and rhizome of Rheum species (Dahuang) and the mineral mirabilite (Mangxiao, sodium sulfate decahydrate). In clinical practice, it is often applied topically as a paste or external compress to treat localized inflammatory conditions, including surgical site infections, postoperative wound complications, and acute pancreatitis. Rhubarb contributes bioactive anthraquinones such as emodin and rhein, which exhibit broad-spectrum antibacterial activity and inhibit pro-inflammatory signaling pathways. Mirabilite acts as an osmotic agent, drawing out fluid to reduce tissue edema and promote the clearance of inflammatory exudates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhubarb + mirabilite.